PRAX May 2024 55.000 put
| Previous close | 8.50 |
| Open | 8.50 |
| Bid | 7.90 |
| Ask | 12.00 |
| Strike | 55.00 |
| Expiry date | 2024-05-17 |
| Day's range | 8.50 - 8.50 |
| Contract range | N/A |
| Volume | |
| Open interest | 42 |
GlobeNewswirePraxis Precision Medicines to Participate in Upcoming Investor Conferences
BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences. Praxis management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conferenc
Simply Wall St.We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Praxis...
- GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre-screening forms and over 7,000 referrals received to date that meet pre-qualifying eligibility criteria; topline results expected in the second half of 2024 Randomization in PRAX-562 Phase 2 EMBOLD study completed in pediatric patients with
